A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17

BACKGROUND: Gastrointestinal stromal tumors (GISTs) are caused by the constitutive activation of KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutations. Imatinib selectively inhibits KIT and PDGFR, leading to disease control for 80%–90% of patients with metastatic GIST. Imatinib res...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeh, Chun-Nan, Chen, Ming-Huang, Chen, Yen-Yang, Yang, Ching-Yao, Yen, Chueh-Chuan, Tzen, Chin-Yuan, Chen, Li-Tzong, Chen, Jen-Shi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546467/
https://www.ncbi.nlm.nih.gov/pubmed/28487491
http://dx.doi.org/10.18632/oncotarget.17310

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546467/
https://www.ncbi.nlm.nih.gov/pubmed/28487491
http://dx.doi.org/10.18632/oncotarget.17310

Ejemplares similares